NCT05788497终止3 期
Multicentre, Double-blind, Randomised Clinical Trial to Evaluate and Compare the Efficacy and Safety of Hemorrane Plus (Hemorrane® + Benzocaine) With Hemorrane® and With Placebo in Patients With Uncomplicated Haemorrhoids
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 13
- 主要终点
- Percentage of responders at T156h +30 min (day 7 hour 12 + 30min) compared to T0 (day 1 hour 0), for Hemorrane Plus and placebo; as well as the percentage of responders within 30 minutes after the application of Hemorrane Plus and Hemorrane®.
研究概览
简要总结
This is a Multicentre, double-blind, randomised clinical trial to evaluate and compare the efficacy and safety of Hemorrane Plus (Hemorrane® + benzocaine) with Hemorrane® and with placebo in patients with uncomplicated haemorrhoids.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Over 18s and both sexes.
- •Voluntary signing of informed consent.
- •Diagnosis of uncomplicated haemorrhoids: grade I or II non-thrombosed external, mixed, or internal haemorrhoids.
- •VAS of pain ≥ 5 points.
- •VAS of pruritus and stinging/burning ≥ 5 points (for each one).
- •Commitment to comply with the hygienic-dietary measures established for the general management of haemorrhoids.
- •Negative urine pregnancy test (women of childbearing age, if applicable).
- •Patients with adequate understanding of the study and ability to perform the procedures independently.
排除标准
- •History of hypersensitivity to any of the active ingredients or components of the investigational products, as well as hypersensitivity to other local anaesthetics derived from para-aminobenzoic acid (PABA), parabens, or paraphenylenediamine (for example, hair dyes, henna tattoos).
- •Use of topical haemorrhoid medications or other topical agents for the anorectal area less than 48 hours before the start of the study (Visit 1, day 1).
- •Haemorrhoidal surgery that is scheduled between Visit 1 (day 1) and the follow-up visit Visit 3 (day 15±2).
- •Diagnosis of grade III or IV thrombosed external or internal haemorrhoids.
- •Medical history of anaemia, and/or current diagnosis of cardiac or pulmonary disease, shock, sepsis, acidosis, or genetic predisposition (NADH-cytochrome b5 reductase deficiency, glucose-6-phosphate dehydrogenase deficiency, and haemoglobin M disease); that include risk factors for methemoglobinemia.
- •Documented diagnosis of active tuberculosis.
- •Active bleeding haemorrhoids.
- •Presence of pain, stinging/burning, pruritus, anorectal bleeding or rectal bleeding for causes other than haemorrhoidal disease.
- •Presence of bacterial, viral, and/or fungal infections in the perianal area.
- •History of pancreatic pathology that may require performance of a bentiromide diagnostic test.
- •Use of any of the prohibited concomitant medications (sulfonamides, cholinesterase inhibitors, ester or prilocaine-type local anaesthetics, sodium nitrite, neurotoxic insecticides (topical malathion), aminosalicylic acid, suxamethonium, antiarrhythmics, monoamine oxidase inhibitors, tricyclic antidepressants, and PABA derivatives) less than one week prior to the start of the study (Visit 1, Day 1), or throughout the study.
- •Use of any hair dye, including those containing paraphenylene-diamine during the study, from Visit 1 (Day 1) to the follow-up Visit 3 (Day 15 ± 2).
- •Any other circumstance considered by the investigator to prevent adequate follow-up and/or adequate evolution of the response to the study treatments.
- •Pregnant women, those planning an upcoming pregnancy or breast-feeding.
- •Women of childbearing age who do not agree to take the pregnancy test and use valid contraceptive methods during the study and until the end of the use of the investigational treatment. The following are considered valid contraceptive methods: combined hormonal oral, intravaginal or transdermal contraceptives (oestrogen and progesterone), oral, injectable or implantable progesterone-based hormonal contraceptives, intrauterine device (IUD), hormone-releasing intrauterine device, bilateral tubal occlusion, vasectomised partner (as long as they are the only sexual partner of the participating patient and that the success of the intervention has been medically confirmed), or sexual abstinence (abstaining from heterosexual intercourse during the treatment period). The investigator is responsible for determining whether the patient has an appropriate contraceptive method for her participation in the study.
- •Fertile men who use condoms or have had a vasectomy (as long as the success of the intervention has been medically confirmed), or who practise abstinence (abstinence from heterosexual sexual relationships during the treatment period). The investigator is responsible for determining whether the patient has an appropriate contraceptive method for their participation in the study.
- •Patients who have had active cancer in the last five years.
- •Patients who have received an investigational drug (including vaccines) or who have used an invasive medical device in the last 30 days prior to the start of the screening phase or who are currently participating in another clinical trial.
- •Patients who have a family or professional relationship with the research team participating in the clinical study.
研究组 & 干预措施
Hemorrane® Plus
Experimental
Daily application of Hemorrane Plus (Hemorrane® + benzocaine) 10 mg/g rectal ointment + 30 mg/g benzocaine for 7 days.
干预措施: Hemorrane plus (Drug)
Hemorrane®
Active Comparator
Daily application of Hemorrane 10 mg/g rectal ointment for 7 days.
干预措施: Hemorrane (Drug)
Placebo
Placebo Comparator
Daily application of placebo for 7 days.
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of responders at T156h +30 min (day 7 hour 12 + 30min) compared to T0 (day 1 hour 0), for Hemorrane Plus and placebo; as well as the percentage of responders within 30 minutes after the application of Hemorrane Plus and Hemorrane®.
时间窗: 7 days 12 hours 30 min
Responders are defined as those patients with a decrease of two or more points out of ten on the Visual Analogue Scale (VAS) of pain (assessed by the patient).
次要结局
- Evaluation of the mean values of the bleeding episodes recorded (assessed by the investigator) at Visit 1 (Screening and baseline), and at Visit 2 (day 8+1), for the three treatments.(7 days 12 hours 30 min)
- Percentage of responders at T156h +30 min (day 7 hour 12 + 30min) compared to T0 (day 1 hour 0), for Hemorrane Plus and Hemorrane®(7 days 12 hours 30 min)
- Change in the VAS of stinging/burning (assessed by the patient), at the established times, compared to the baseline value (T0), for the three treatments.(7 days 12 hours 30 min)
- Incidence of topical allergic reactions(7 days 12 hours 30 min)
- Change in the VAS of pruritus (assessed by the patient), at the established times, compared to the baseline value (T0), for the three treatments.(7 days 12 hours 30 min)
- Percentage of responders at T156h +30 min (day 7 hour 12 + 30 min) compared to T0 (day 1 hour 0), for Hemorrane® Plus versus placebo(7 days 12 hours 30 min)
- Description of local tolerability and satisfaction(7 days 12 hours 30 min)
- Percentage of patients withdrawn from the study for safety reasons(7 days 12 hours 30 min)
- Change in the VAS of inflammation (assessed by the investigator) at Visit 2 (day 8+1), compared to baseline (T0), for the three treatments.(7 days 12 hours 30 min)
- Change in the patient's quality of life measured with the EQ-5D-5L questionnaire, at Visit 2 (day 8+1) compared to the baseline value at Visit 1 (day 1, T0), for the three treatments(7 days 12 hours 30 min)
- Incidence of adverse events (AE)(7 days 12 hours 30 min)
- Percentage of clinically significant changes in haematology, biochemistry, and methaemoglobin analysis compared to baseline.(15 +/- 2 days)
研究者
研究点 (13)
Loading locations...
相似试验
招募中
3 期
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）Ischemic Stroke, AcuteSymptomatic Intracranial Artery StenosisTIANCT06319846Beijing Tiantan Hospital4,674
进行中（未招募）
不适用
Treatment of Knee Osteoarthritis With PAAG-OAOsteoarthritis, KneeNCT04045431Contura238
已完成
3 期
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyRheumatoid ArthritisNCT02167139Samsung Bioepis Co., Ltd.544
已完成
3 期
A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyRheumatoid ArthritisNCT01895309Samsung Bioepis Co., Ltd.596
已完成
3 期
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyRheumatoid ArthritisNCT01936181Samsung Bioepis Co., Ltd.584